LXRX

Business Context and Reporting Period

Company: Lexicon Pharmaceuticals, Inc. (LXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 4, 2026
Event: Entry into a Material Definitive Agreement (Loan and Security Agreement) with Hercules Capital, Inc. and affiliates.

Key Financial Metrics and Capital Structure

Debt Facility: Up to $100 million in borrowing capacity structured in three tranches, maturing in May 2030.
Funding Status: First tranche of $55 million funded at closing. Second tranche ($20 million) and third tranche ($25 million) are available subject to milestones and timing constraints.
Interest Rate: Floating rate equal to Prime Rate + 3.10%, with a floor of 9.85%.
Equity Component: Warrants granted to purchase 2% of the aggregate principal amount funded at an exercise price of $1.59 per share. Initial grant covers 691,823 shares.
Security: First lien security interest in all assets of Lexicon and its subsidiaries.
Prepayment Penalty: 3.0% of outstanding principal (declining scale).
Final Payment: 6.25% of the amount funded due upon prepayment or maturity.

Material Changes and Covenants

Repayment Structure: Interest-only payments for an initial 18 months, extendable to 24 or 30 months based on clinical and financial milestones. Followed by an amortization period through maturity.
Performance Milestones: Extension of the interest-only period is contingent on the SONATA-HCM Phase 3 clinical trial of sotagliflozin achieving its primary endpoint with an acceptable safety profile and meeting specified financial requirements.
Financial Covenants:

• Minimum Cash Covenant: Effective June 1, 2027 (extendable to Jan 1, 2028 if milestones met); waived if market capitalization requirements are met.
• Minimum Revenue Covenant: Applies to net sales after drawing the second or third tranche; waived if minimum cash or market capitalization requirements are met.

Other Covenants: Restrictions on dispositions, mergers, acquisitions, additional indebtedness, encumbrances, distributions, and affiliate transactions.

Outlook, Risks, and Contingencies

Strategic Outlook: The financing is designed to support the commercialization strategy for sotagliflozin in the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy (HCM).
Risks:

• Default Risk: An event of default allows Hercules to declare all amounts immediately due and payable.
• Dilution Risk: Issuance of unregistered warrants (total potential of 1,257,860 shares across all tranches) exercisable over five years.
• Operational Risk: Access to additional funding tranches and extension of favorable interest-only terms depend on the success of the Phase 3 clinical trial and regulatory approval.

Unusual Items: The filing includes a 6.25% final payment fee upon maturity or prepayment, which is a significant cost of capital beyond the interest rate.

Investor Verification Checklist

• Verify the current status of the SONATA-HCM Phase 3 clinical trial and whether primary endpoints have been met to trigger tranche availability.
• Confirm the company's current cash balance against the minimum cash covenant effective June 1, 2027.
• Assess the impact of the 6.25% final payment fee and 3.0% prepayment penalty on the total cost of capital.
• Review the dilution impact of the 691,823 initial warrants and potential future warrants (up to 1,257,860 total) at the $1.59 exercise price.
• Monitor the company's market capitalization to determine if covenants are waived based on market cap thresholds.